Zobrazeno 1 - 10
of 11
pro vyhledávání: '"M L Barzelloni"'
Autor:
Antonio Rossi, M L Barzelloni, Francesca Casaluce, Paola Claudia Sacco, Cesare Gridelli, Giovanni Palazzolo, Assunta Sgambato, Paolo Maione, Giuseppe Santabarbara
Publikováno v:
Expert Opinion on Drug Safety. 16:471-479
Non-small-cell lung cancer (NSCLC) patients after first-line therapy ultimately suffer progression. At this time, many patients still have a good performance status and can be considered for further active treatment. Two chemotherapeutic agents, doce
Autor:
Claudia Mucciarini, M L Barzelloni, Olga Martelli, Orazio Caffo, Antonio Rossi, Alessandro Follador, V. Filipazzi, Massimo Di Maio, Pier Luigi Piovano, Alessandra Bearz, Erika Rijavec, Giuseppe Luigi Banna, Giovenzio Genestreti, Fausto Barbieri, Tiziana Vavalà, Nicoletta Zilembo, Alessandro Morabito, Diego Cortinovis, Silvia Novello, F.L. Cecere, Marcello Tiseo, Elisa Rizzo, C. Casartelli, Jessica Menis, Emilio Bria, Domenico Galetta, Gianluca Spitaleri, Antonio Ardizzoia
Publikováno v:
Lung Cancer. 95:73-81
Objectives Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9–12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-lin
Autor:
Olga Martelli, Jessica Menis, Nicoletta Zilembo, M L Barzelloni, Pier Luigi Piovano, Tiziana Vavalà, Marcello Tiseo, Orazio Caffo, Sara Pilotto, Claudia Mucciarini, Alessandro Follador, Erika Rijavec, Antonio Ardizzoia, Fausto Barbieri, Gianluca Spitaleri, Elisa Rizzo, Diego Cortinovis, C. Casartelli, Antonio Rossi, Alessandra Bearz, Silvia Novello, Giuseppe Luigi Banna, Emilio Bria, Alessandro Morabito, Domenico Galetta, Giovenzio Genestreti, F.L. Cecere, Massimo Di Maio, V. Filipazzi
Publikováno v:
Clinical lung cancer. 19(1)
Background Beyond progression after tyrosine kinase inhibitor in EGFR -positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth fa
Autor:
Paolo Maione, Cesare Gridelli, M L Barzelloni, G. Colantuoni, G. Airoma, Vincenzo Castaldo, Carmine Ferrara, Antonio Rossi
Publikováno v:
Scopus-Elsevier
Breast cancer arises in about 48% of patients older than 65 years and more than 30% occurs in those over 70 years being the leading cause of cancer-related death in women older than 65. Elderly patients tolerate chemotherapy poorly compared to their
Publikováno v:
European Journal of Cancer Supplements. 2:15-25
Non-small cell lung cancer (NSCLC) may be considered typical of advanced age. More than 50% of NSCLC patients are diagnosed over the age of 65 and approximately one-third of all patients with non-small cell lung cancer (NSCLC) are over the age of 70.
Autor:
M L Barzelloni, R. Cioffi, C. Gridelli, A. Rossi, F. Perrone, Luciano Frontini, Enzo Veltri, M Grazia Caprio, Ciro Gallo, Domenico Bilancia, Emiddio Barletta, Luigi Manzione
Publikováno v:
British Journal of Cancer
A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m23-h infusion) every 4 weeks in the first line treatment of patients affected by e
Autor:
Emiddio Barletta, C. Guida, M L Barzelloni, Roberta D’Aniello, Cesare Gridelli, Francesco Fiore, Tindaro Gatani, Mario De Bellis, Antonio Rossi, Francesco Scognamiglio
Publikováno v:
Lung Cancer. 29:131-137
Experimental studies have shown that vinorelbine is a powerful radiosensitizer in vitro. To date, no reports on clinical activity of the single agent vinorelbine as radiosensitizer have been published. The aim of the present phase I study was to dete
Autor:
R D’Aniello, L. Manzione, G P Ianniello, L. Brancaccio, S. Cigolari, C. Gridelli, Domenico Bilancia, Emiddio Barletta, P. Masullo, Tonino Pedicini, Carlo Crispino, M L Barzelloni, G. De Cataldis, A. Maiorino, M Di Lanno, Luigi Maiorino, Alessandra Rossi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 28(3)
Purpose : to evaluate the activity and toxicity of the combination cisplatin plus vinorelbine plus amifostine in advanced non small cell lung cancer (NSCLC). Patients and methods : a two-stage Simon design was applied. To proceed after the first stag
Autor:
C, Gridelli, L, Frontini, E, Barletta, A, Rossi, M L, Barzelloni, F, Scognamiglio, C, Guida, T, Gatani, F, Fiore, M, De Bellis, A, Marfella, L, Manzione
Publikováno v:
Anticancer research. 20(2B)
The use of salvage chemotherapy in advanced non small cell lung cancer (NSCLC) is controversial. However, many patients need to be treated in order to achieve relief of their symptoms. Docetaxel (taxotere) is one of the most active drugs for the trea
Autor:
C, Gridelli, F, Perrone, C, Gallo, A, Rossi, E, Barletta, M L, Barzelloni, S, Creazzola, T, Gatani, F, Fiore, C, Guida, F, Scognamiglio
Publikováno v:
Anticancer research. 19(5C)
Although the use of salvage chemotherapy in advanced non-small cell lung cancer (NSCLC) is controversial, pretreated symptomatic patients often need some kind of treatment to achieve symptoms relief. Gemcitabine is one of the most active new drugs in